BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Dai Y, Lu Q, Li P, Zhu J, Jiang J, Zhao T, Hu Y, Ding K, Zhao M. Xianglian Pill attenuates ulcerative colitis through TLR4/MyD88/NF-κB signaling pathway. Journal of Ethnopharmacology 2023;300:115690. [DOI: 10.1016/j.jep.2022.115690] [Reference Citation Analysis]
2 Chu S, Yu T, Wang W, Wu H, Zhu F, Wei C, Gao F, Liu C, Fan H. Exosomes derived from EphB2-overexpressing bone marrow mesenchymal stem cells regulate immune balance and repair barrier function.. [DOI: 10.21203/rs.3.rs-2040313/v1] [Reference Citation Analysis]
3 Celani LMS, Egito EST, Azevedo ÍM, Oliveira CN, Dourado D, Medeiros AC. Treatment of colitis by oral negatively charged nanostructured curcumin in rats. Acta Cir Bras 2022;37:e370602. [PMID: 35976279 DOI: 10.1590/acb370602] [Reference Citation Analysis]
4 Chen Y, Shen J. Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review. eClinicalMedicine 2022;46:101382. [DOI: 10.1016/j.eclinm.2022.101382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Che Y, Yu Z, Geng F, He M, Yang Z, Zheng Y, Zhang C, Zhao Y, Wu X, Liu H. Effects of the Traditional Chinese Medicine Formula Ento-PB in Experimental Models of Ulcerative Colitis. Natural Product Communications 2022;17:1934578X2210784. [DOI: 10.1177/1934578x221078453] [Reference Citation Analysis]
6 Han G, Cho H, Kim H, Jang Y, Jang H, Kim DE, Kim ES, Kim EH, Hwang KY, Kim K, Yang Y, Kim SH. Bovine colostrum derived-exosomes prevent dextran sulfate sodium-induced intestinal colitis via suppression of inflammation and oxidative stress. Biomater Sci 2022. [PMID: 35315847 DOI: 10.1039/d1bm01797g] [Reference Citation Analysis]
7 Wang YJ, Li QM, Zha XQ, Luo JP. Dendrobium fimbriatum Hook polysaccharide ameliorates dextran-sodium-sulfate-induced colitis in mice via improving intestinal barrier function, modulating intestinal microbiota, and reducing oxidative stress and inflammatory responses. Food Funct 2021. [PMID: 34874039 DOI: 10.1039/d1fo03003e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
8 Li J, Hou W, Lin S, Wang L, Pan C, Wu F, Liu J. Polydopamine Nanoparticle-Mediated Dopaminergic Immunoregulation in Colitis. Adv Sci (Weinh) 2022;9:e2104006. [PMID: 34713621 DOI: 10.1002/advs.202104006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Ochman B, Kula A, Świętochowska E. The functional role of miRNAs in inflammatory pathways associated with intestinal epithelial tight junction barrier regulation in IBD. Postępy Higieny i Medycyny Doświadczalnej 2022;76:254-267. [DOI: 10.2478/ahem-2022-0038] [Reference Citation Analysis]
10 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kishimoto K, Nozaki Y, Sakurai T, Kinoshita K, Funauchi M, Matsumura I. Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals. Life (Basel) 2021;11:1019. [PMID: 34685390 DOI: 10.3390/life11101019] [Reference Citation Analysis]
12 Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 34409654 DOI: 10.1111/jgh.15667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yang QY, Ma LL, Zhang C, Lin JZ, Han L, He YN, Xie CG. Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota. Front Pharmacol 2021;12:674416. [PMID: 34366843 DOI: 10.3389/fphar.2021.674416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Ozgur I, Kulle CB, Buyuk M, Ormeci A, Akyuz F, Balik E, Bulut T, Keskin M. What are the predictors for recurrence of Crohn's disease after surgery? Medicine (Baltimore) 2021;100:e25340. [PMID: 33832109 DOI: 10.1097/MD.0000000000025340] [Reference Citation Analysis]
15 Serrya MS, El-Sheakh AR, Makled MN. Evaluation of the therapeutic effects of mycophenolate mofetil targeting Nrf-2 and NLRP3 inflammasome in acetic acid induced ulcerative colitis in rats. Life Sci 2021;271:119154. [PMID: 33539910 DOI: 10.1016/j.lfs.2021.119154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Vrdoljak J, Vilović M, Živković PM, Tadin Hadjina I, Rušić D, Bukić J, Borovac JA, Božić J. Mediterranean Diet Adherence and Dietary Attitudes in Patients with Inflammatory Bowel Disease. Nutrients 2020;12:E3429. [PMID: 33171662 DOI: 10.3390/nu12113429] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
17 Shin DW, Lim BO. Nutritional Interventions Using Functional Foods and Nutraceuticals to Improve Inflammatory Bowel Disease. J Med Food 2020;23:1136-45. [PMID: 33047999 DOI: 10.1089/jmf.2020.4712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Muller M, Broséus J, Feugier P, Thieblemont C, Beaugerie L, Danese S, Arnone D, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L. Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2021;15:827-39. [PMID: 32949235 DOI: 10.1093/ecco-jcc/jjaa193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, Magnano A, Pluchino D, Camilleri S, Garufi S, Mitri RD, Mocciaro F, Magrì G, Ferracane C, Citrano M, Graziano F, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Dig Liver Dis 2020;52:1461-6. [PMID: 32601033 DOI: 10.1016/j.dld.2020.06.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
20 Almási N, Török S, Dvorácskó S, Tömböly C, Csonka Á, Baráth Z, Murlasits Z, Valkusz Z, Pósa A, Varga C, Kupai K. Lessons on the Sigma-1 Receptor in TNBS-Induced Rat Colitis: Modulation of the UCHL-1, IL-6 Pathway. Int J Mol Sci 2020;21:E4046. [PMID: 32516975 DOI: 10.3390/ijms21114046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
21 Hardy AJ, Stoica I, Kearney DE, O'Riordain DS. Diffuse large B-cell lymphoma of the rectum in a patient with Crohn's disease. BMJ Case Rep 2020;13:e228818. [PMID: 32303524 DOI: 10.1136/bcr-2018-228818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Marin-Jimenez I, Bastida G, Forés A, Garcia-Planella E, Argüelles-Arias F, Sarasa P, Tagarro I, Fernández-Nistal A, Montoto C, Aguas M, Santos-Fernández J, Bosca-Watts MM, Ferreiro R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, Barreiro-de Acosta M. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study. BMJ Open Gastroenterol 2020;7:e000351. [PMID: 32337054 DOI: 10.1136/bmjgast-2019-000351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liu H, Liang Z, Wang F, Zhou C, Zheng X, Hu T, He X, Wu X, Lan P. Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism. JCI Insight 2019;4:131273. [PMID: 31689240 DOI: 10.1172/jci.insight.131273] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 27.3] [Reference Citation Analysis]
24 Saigusa N, Saigusa JI, Shinozaki M, Yokoyama T, Yokoi Y, Takami H, Miyahara R, Yokoyama Y. A series of seton techniques involving "top-down therapy" for patients with Crohn's disease who initially presented with perianal fistulas. J Anus Rectum Colon 2018;2:122-9. [PMID: 31559354 DOI: 10.23922/jarc.2017-044] [Reference Citation Analysis]
25 Wang JJ, Fan YH. Advances in research of tacrolimus for treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(13): 842-850 [DOI: 10.11569/wcjd.v27.i13.842] [Reference Citation Analysis]
26 Bodini G, Zanella C, Crespi M, Lo Pumo S, Demarzo MG, Savarino E, Savarino V, Giannini EG. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition 2019;67-68:110542. [PMID: 31470260 DOI: 10.1016/j.nut.2019.06.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
27 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
28 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 19.3] [Reference Citation Analysis]
29 Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH, Shin JI. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev 2019;18:439-54. [PMID: 30844556 DOI: 10.1016/j.autrev.2019.03.002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 23.7] [Reference Citation Analysis]
30 Yamamoto-furusho J, Sarmiento-aguilar A, Parra-holguín N, Bozada-gutiérrez K. Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. Revista de Gastroenterología de México (English Edition) 2019;84:11-17. [DOI: 10.1016/j.rgmxen.2018.05.001] [Reference Citation Analysis]
31 Mai CT, Wu MM, Wang CL, Su ZR, Cheng YY, Zhang XJ. Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation. Mol Immunol 2019;105:76-85. [PMID: 30496979 DOI: 10.1016/j.molimm.2018.10.015] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 18.8] [Reference Citation Analysis]
32 Amine L, Abdelgadir IS, Neves K, Elawad M, Hassan A, Akobeng AK. Tacrolimus for induction therapy in active Crohn's disease. Cochrane Database of Systematic Reviews 2018. [DOI: 10.1002/14651858.cd013142] [Reference Citation Analysis]
33 Brady JE, Stott-miller M, Mu G, Perera S. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. Clinical Therapeutics 2018;40:1509-1521.e5. [DOI: 10.1016/j.clinthera.2018.07.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
34 Ma X, Hu Y, Li X, Zheng X, Wang Y, Zhang J, Fu C, Geng F. Periplaneta americana Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota Regulation. Front Pharmacol. 2018;9:944. [PMID: 30186174 DOI: 10.3389/fphar.2018.00944] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
35 Mijan MA, Lim BO. Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. World J Gastroenterol 2018; 24(25): 2673-2685 [PMID: 29991873 DOI: 10.3748/wjg.v24.i25.2673] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 65] [Article Influence: 16.0] [Reference Citation Analysis]
36 Celiberto LS, Graef FA, Healey GR, Bosman ES, Jacobson K, Sly LM, Vallance BA. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology 2018;155:36-52. [PMID: 29693729 DOI: 10.1111/imm.12939] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 17.0] [Reference Citation Analysis]
37 Yamamoto-Furusho JK, Sarmiento-Aguilar A, Parra-Holguín NN, Bozada-Gutiérrez KE. Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. Rev Gastroenterol Mex (Engl Ed) 2019;84:11-7. [PMID: 29605092 DOI: 10.1016/j.rgmx.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 586] [Cited by in F6Publishing: 609] [Article Influence: 146.5] [Reference Citation Analysis]
39 Courthion H, Mugnier T, Rousseaux C, Möller M, Gurny R, Gabriel D. Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis. J Control Release 2018;275:32-9. [PMID: 28774843 DOI: 10.1016/j.jconrel.2017.07.044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
40 Mazzola G, Macaluso FS, Adamoli L, Renna S, Cascio A, Orlando A. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. J Infect. 2017;74:433-441. [PMID: 28263759 DOI: 10.1016/j.jinf.2017.02.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
41 Clowry J, Sheridan J, Healy R, Deady S, Keegan D, Byrne K, Cullen G, Mulcahy H, Comber H, Parnell A, Doherty G, Lally A. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study. J Eur Acad Dermatol Venereol 2017;31:978-85. [DOI: 10.1111/jdv.14105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
42 Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Digestive and Liver Disease 2017;49:157-62. [DOI: 10.1016/j.dld.2016.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Actis GC. Biologics for Ulcerative Colitis: Status of the Art and General Considerations. Ann Colorectal Res 2016;Inpress. [DOI: 10.17795/acr-42868] [Reference Citation Analysis]
44 Actis GC. Biologics for Ulcerative Colitis: Status of the Art and General Considerations. Ann Colorectal Res 2016;5. [DOI: 10.5812/acr.42868] [Reference Citation Analysis]
45 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
46 Vasanth P, Parmley M, Torrealba J, Hamdi T. Interstitial Nephritis in a Patient with Inflammatory Bowel Disease. Case Rep Nephrol 2016;2016:4260365. [PMID: 27703822 DOI: 10.1155/2016/4260365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Bosma M, Gerling M, Pasto J, Georgiadi A, Graham E, Shilkova O, Iwata Y, Almer S, Söderman J, Toftgård R, Wermeling F, Boström EA, Boström PA. FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice. Nat Commun 2016;7:11314. [PMID: 27066907 DOI: 10.1038/ncomms11314] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
48 Larche M, McGonagle D. A case of resistant spondyloarthritis (SpA) that responded to tacrolimus and mycophenolate treatment initiated at the time of renal transplantation for unrelated renal failure. Scand J Rheumatol 2017;46:158-9. [PMID: 26971928 DOI: 10.3109/03009742.2016.1148774] [Reference Citation Analysis]
49 Saigusa N, Saigusa J, Yokoyama T, Oosawa T, Ishiguro S, Shinozaki M, Kikuchi M, Yokoyama Y. “Top Down Therapy” for Patients with Crohn's Disease who Initially Presented with Anorectal Fistula May Improve Perianal and Bowel Disease. Journal of Japan Society of Coloproctology 2016;69:424-429. [DOI: 10.3862/jcoloproctology.69.424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Guo X, Guo R, Luo X, Zhou L. Ethyl pyruvate ameliorates experimental colitis in mice by inhibiting the HMGB1-Th17 and Th1/Tc1 responses. International Immunopharmacology 2015;29:454-61. [DOI: 10.1016/j.intimp.2015.10.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
51 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
52 Shi YH, Weng Y, Liu ZJ. Detection of serum infliximab concentration for evaluation of treatment efficacy in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
53 Corica D, Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis. 2016;10:226-235. [PMID: 26223844 DOI: 10.1093/ecco-jcc/jjv138] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 10.6] [Reference Citation Analysis]
54 Vecchi Brumatti L, Marcuzzi A, Tricarico PM, Zanin V, Girardelli M, Bianco AM. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules. 2014;19:21127-21153. [PMID: 25521115 DOI: 10.3390/molecules191221127] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 11.1] [Reference Citation Analysis]